Physician profile
Mani Razmjoo
NPI 1104245208
$840.25
in general payments reported to CMS, 2019-2025
11 companies · $120 in 2025
The $120 reported for 2025 was less than what a typical Vascular & Interventional Radiology provider received nationally (typical 2025 total: $537).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $257 · 2020: $179 · 2022: $134 · 2023: $110 · 2024: $40.26 · 2025: $120.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $270.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $269.58 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Penumbra, INC. | $198.97 | 2020-2023 | Ruby Coil |
| Biocompatibles, INC. | $121.21 | 2019 | |
| Medtronic, INC. | $119.58 | 2025 | Emprint |
| Cook Medical LLC | $117.84 | 2020 | |
| Boston Scientific Corporation | $84.67 | 2019-2023 | |
| E.R. Squibb & Sons, L.L.C. | $69.21 | 2019 | |
| Terumo Medical Corporation | $38.83 | 2022-2024 | Azur Cx Detachable |
| Ethicon US, LLC | $35.15 | 2023 | Neuwave |
| Incyte Corporation | $20.52 | 2019 | |
| Hologic Sales and Service, LLC | $17.20 | 2024 | Localizer |
| Lilly USA, LLC | $17.07 | 2019 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Mani Razmjoo listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.